A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Vonlerolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 02 Jul 2019 Planned End Date changed from 3 Dec 2019 to 10 Jan 2020.
- 25 Mar 2019 Planned End Date changed from 8 Mar 2019 to 3 Dec 2019.
- 10 Sep 2018 Planned End Date changed from 3 Nov 2018 to 8 Mar 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History